Abstract
Background
The last few decades have seen significant advances in our understanding of the neurochemical basis of schizophrenia.
Aims
To describe the neurotransmitter systems and nerve circuits implicated in schizophrenia; to compare the neuropharmacology of typical and atypical anti-psychotic agents; and to describe recent developments in the pharmacological treatment of schizophrenia.
Methods
Relevant pharmacological, neurophysiological and psychiatric literature was examined and reviewed.
Results
Schizophrenia is associated with abnormalities of multiple neurotransmitter systems, including dopamine, serotonin, gamma-aminobutyric acid and glutamate. Typical and atypical antipsychotic agents differ in their receptorbinding affinities, which are related to their differing side-effect profiles. Novel therapeutic strategies include normalisation of synaptic dopamine or serotonin levels, serotonin receptor antagonism and modulation of cerebral protein synthesis.
Conclusions
The ideal treatment for schizophrenia may not be a single pharmacological agent but several agents that match the different expressions of the illness, in combination with psycho-social interventions.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Torrey EF. Prevalence studies in schizophrenia.Br J Psychiatry 1987; 150: 598–608.
Jablensky A. The 100-year epidemiology of schizophrenia.Schizophr Res 1997; 28: 111–28.
Daly A, Walsh D. Irish Psychiatric Services: Activities 2000. Dublin: Health Research Board, 2001.
Kahn, Rene S, Davis Kenneth L. New Developments in Dopamine and Schizophrenia. The American College Of Neuropsychopharmacology 2000.
Gelder M, Gath D, Mayou R, Cowen P. Oxford Textbook of Psychiatry (3rd edition), Oxford University Press, Oxford 1996.
Abi-Dargham A, Guo NN, Lombardo I et al. Selective Upregulation Of Prefrontal D1 Receptors In Schizophrenia Predicts Poor Working Memory Performance. NeuroReceptor Mapping 2002 Meeting. Elsevier Science, New York 2002.
Rang HP, Dale MM, Ritter JM et al. Pharmacology. Churchill Livingstone, New York 1999.
Roth BL, Meltzer HY. The role of serotonin in schizophrenia. The American College Of Neuropsychopharmacology, New York 2000.
Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favourable molecular targets for cognitive enhancement in schizophrenia and other disorders.Psychopharmacol (Berl) 2004; 174: 17–24.
Fan JB, Sklar P. Meta-analysis reveals association between serotonin transporter gene STin2 VNTR polymorphism and schizophrenia.Mol Psychiatry 2004 Aug 31 [Epub ahead of print] (available at http://www.nature.com/mp/journal/vaop/ncurrent/).
Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics, McGraw Hill, New York 1996.
Kaplan VA, Sadcock BJ. Comprehensive Textbook of Psychiatry. Lippencott Williams & Wilkins, New York 1995.
Gluck MR, Thomas RG, Davis KL, Haroutunian V. Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.Am J Psychiatry 2002; 159: 1165–73.
Berretta S, Munno DW, Benes FM. Amygdalar activation alters the hippocampal GABA system: “partial” modelling for postmortem changes in schizophrenia.J Comp Neurol 2001; 431: 129–38.
O’Connor WT. Functional neuroanatomy of the ventral striopallidal GABA pathway. New sites of intervention in the treatment of schizophrenia.J Neurosci Methods 2001; 109: 31–9.
Diaz-Cabiale Z, Vivo M, Del Arco A et al. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors.Neurosci Lett 2002; 324: 154–8.
O’Connor WT. Functional neuroanatomy of the basal ganglia as studied by dual-probe microdialysis.Nucl Med Biol 1998; 25: 743–6.
Fendt M. Enhancement of prepulse inhibition after blockade of GABA activity within the superior colliculus. Brain Res 1999; 833: 81–5.
Fendt M, Schwienbacher I, Koch M. Amygdaloid N-methyl-D-aspartate and gamma-aminobutyric acid(A) receptors regulate sensorimotor gating in a dopamine-dependent way in rats.Neuroscience 2000; 98: 55–60.
Bunney G. B., Bunney Jr., W.E., Carlsson A. Schizophrenia and Glutamate: An update. The American College Of Neuropsychopharmacology, New York 2000.
McEvoy JP, Scheifler Pl, Frances A. Expert consensus guideline series. Treatment of schizophrenia.J Clin Psychiatry 1999; 60 Suppl 11: 3–80.
Seeman P. Atypical antipsychotics: mechanism of action.Can J Psychiatry 2002; 47: 27–38.
Meltzer HY. Atypical antipsychotic drugs. The American College Of Neuropsychopharrnacology, New York 2000.
Wadenberg ML, Soliman A, VanderSpek SC et al. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.Neuropsychopharmacol 2001; 25: 633–41.
Tamminga CA. Partial dopamine agonists in the treatment of psychosis.J Neural Transm 2002; 109: 411–20.
Lieberman JA. Dopamine partial agonists: a new class of antipsychotic.CNS Drugs 2004; 18: 251–67.
Moises Hans WM. Human Genome data analyzed by an evolutionary method suggests a decrease in cerebral protein-synthesis rate as cause of schizophrenia and an increase as antipsychotic mechanism.BioMed Central Psychiatry 2002; 2: 8 (available at www.biomedcentral.com).
Albert KA, Hemmings HC Jr, Adamo AI et al. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia.Arch Gen Psychiatry 2002; 59: 705–12.
Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient.Biol Psychiatry 2001; 50: 873–83.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lyne, J., Kelly, B.D. & O’ Connor, W.T. Schizophrenia: a review of neuropharmacology. Ir J Med Sci 173, 155–159 (2004). https://doi.org/10.1007/BF03167931
Issue Date:
DOI: https://doi.org/10.1007/BF03167931